Memantine hydrochloride - Alzheimers disease
You are here : Home > Formulary Search > Memantine hydrochloride - Alzheimers disease
Status 1
- Oral solution
- Oro-dispersible tablets
- Tablets
As combination therapy - Appropriate for Primary Care initiation when being added to existing AChE inhibitor therapy in patients with worsening cognitive function or other markers of deterioration.
Reserve orodispersible tablets and oral solution for patients who are unable to swallow tablets.
Status 2
- Oral solution
- Oro-dispersible tablets
- Tablets
As monotherapy in patients with severe Alzheimer's or in moderate disease where an AChE is not tolerated.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
PAD Profile
Committee Recommendations (2)
As part of the Surrey Heartlands Joint Formulary review, the Surrey Heartlands APC approved a change in traffic light status for patients requiring treatment with memantine as monotherapy:
- Blue - on specialist recommendation (previously Amber with shared care for patients who were not suitable for discharge and who required ongoing follow-up with the specialist mental health team)
The prescribing of memantine for patients who are not suitable for discharge can be carried out by Primary Care but, the specialist mental health team will retain responsibility for the review and follow-up of patients that continue to require specialist input.
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the updated resource pack for use by primary care prescribers for managing non-cognitive symptoms in people living with dementia.
Other Indications
Below are listed other indications that Memantine hydrochloride is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Alzheimers disease.